- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VALERITAS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 284,15 | +0,05 % | UnitedHealth: Milliarden-Deal voraus | Der unter Druck stehende größte US-Krankenversicherer UnitedHealth trennt sich wohl von einem weiteren Geschäftsbereich. Wie die Nachrichtenagentur Reuters am Wochenende berichtet, verkauft das Unternehmen... ► Artikel lesen | |
| TELADOC HEALTH | 6,620 | +1,49 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Financial Officer Transition | NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial... ► Artikel lesen | |
| THERMO FISHER | 490,80 | -0,19 % | Price Over Earnings Overview: Thermo Fisher Scientific | ||
| ROKU | 85,72 | -0,29 % | NextTrip, Inc.: NextTrip's JOURNY Expands Global Reach with Launch on Apple iOS, Roku, and Android | New Apps Deepen Audience Engagement and Extend JOURNY's Rebrand Momentum Across Major Platforms SANTA FE, NEW MEXICO / ACCESS Newswire / December 4, 2025 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip,"... ► Artikel lesen | |
| RESMED | 222,70 | +1,09 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| HENRY SCHEIN | 62,26 | -1,52 % | Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment | ||
| ZIMMER BIOMET | 80,96 | 0,00 % | Zimmer Biomet Announces FDA Clearance For Enhanced Version Of ROSA Knee System | SEOUL (dpa-AFX) - Zimmer Biomet Holdings, Inc. (ZBH) announced FDA 510(k) clearance of ROSA Knee with OptimiZe, an enhanced version of its ROSA Knee System. Zimmer Biomet will conduct a targeted... ► Artikel lesen | |
| PETMED EXPRESS | 1,450 | +2,87 % | PetMed Express, Inc.: PetMeds Extends Existing Shareholder Rights Plan | DELRAY BEACH, Fla., Nov. 26, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company"), today announced that its Board of Directors... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| TANDEM DIABETES | 17,280 | -3,84 % | Tandem Diabetes Care beruft Sandra Beaver in den Verwaltungsrat | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| QUIDELORTHO | 24,200 | +0,83 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,490 | +2,89 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 157,55 | +0,51 % | Quest Diagnostics to offer Octave's MS blood test nationwide | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 | All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495... ► Artikel lesen |
Das Unternehmen VALERITAS HOLDINGS INC kann der Branche Gesundheitswesen zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALERITAS HOLDINGS INC finden Sie auf Wallstreet Online.